Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Ravi Munuganti"'
Autor:
Fraser D. Johnson, John Ferrarone, Alvin Liu, Christina Brandstädter, Ravi Munuganti, Dylan A. Farnsworth, Daniel Lu, Jennifer Luu, Tianna Sihota, Sophie Jansen, Amy Nagelberg, Rocky Shi, Giovanni C. Forcina, Xu Zhang, Grace S.W. Cheng, Sandra E. Spencer Miko, Georgia de Rappard-Yuswack, Poul H. Sorensen, Scott J. Dixon, Udayan Guha, Katja Becker, Hakim Djaballah, Romel Somwar, Harold Varmus, Gregg B. Morin, William W. Lockwood
Publikováno v:
Cell Reports, Vol 38, Iss 6, Pp 110343- (2022)
Summary: Phenotype-based screening can identify small molecules that elicit a desired cellular response, but additional approaches are required to characterize their targets and mechanisms of action. Here, we show that a compound termed LCS3, which s
Externí odkaz:
https://doaj.org/article/777c0ebba6e744a58fb41d6fac2350cb
Publikováno v:
Proceedings, Vol 22, Iss 1, p 90 (2019)
No targeted therapies exist against aggressive neuroendocrine tumors; hence, these patients are limited to platinum-based chemotherapy that has not advanced in over three decades. [...]
Externí odkaz:
https://doaj.org/article/f479151c6891444a8e09ee47a83b7033
Autor:
Daksh Thaper, Ravi Munuganti, Adeleke Aguda, Soojin Kim, Shengyu Ku, Olena Sivak, Sahil Kumar, Sepideh Vahid, Dwaipayan Ganguli, Himisha Beltran, Colm Morrissey, Eva Corey, Amina Zoubeidi
The increased incidence of treatment-emergent neuroendocrine prostate cancer (NEPC) is particularly alarming as this diagnosis is associated with poor prognosis. Despite initial responses to platinum-based chemotherapy, relapses are common and there
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9375bc995eb9f52938f4d924e18dc2eb
https://doi.org/10.1101/2022.05.04.490172
https://doi.org/10.1101/2022.05.04.490172
Autor:
Daksh Thaper, Ravi Munuganti, Shaghayegh Nouruzi, Sahil Kumar, Soojin Kim, Olena Sivak, Adeleke Aguda, Dwaipayan Ganguli, Sepideh Vahid, Loredana Puca, Himisha Beltran, Amina Zoubeidi
Publikováno v:
Cancer Research. 79:1295-1295
Introduction: Resistance to newly developed androgen receptor pathway inhibitors (ARPIs), such as Enzalutamide (ENZ), rapidly emerges and patients generally die within two years. In particular, a subset of patients who relapse following ARPI therapy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::62abcfb0fb4bd3f79954c6fd19d6dec8
https://doi.org/10.1158/1538-7445.am2019-1295
https://doi.org/10.1158/1538-7445.am2019-1295
Publikováno v:
Methods in molecular biology (Clifton, N.J.). 1443
The androgen receptor (AR) is an important regulator of genes responsible for the development and recurrence of prostate cancer. Current therapies for this disease rely on small-molecule inhibitors that block the transcriptional activity of the AR. R
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::2b3d699a09d72690f5397edb4523de5f
https://pubmed.ncbi.nlm.nih.gov/27246333
https://pubmed.ncbi.nlm.nih.gov/27246333